|Videos|September 30, 2022
Clinical Implications of the CHECKMATE 9ER Trial
Author(s)Daniel J. George, MD
Dr Daniel J George reviews long term follow up data from the CHECKMATE 9ER and the implications of the data in the treatment paradigm for patients with advanced renal cell carcinoma.
Advertisement
Episodes in this series
Advertisement
Related to this article
Updated ARC-20 data show casdatifan delivers durable responses and strong survival in clear cell renal cell carcinoma, alone and in key first-line combinations.
SABR improved recurrence-free survival vs historical benchmark with IVC tumor thrombus; investigators hypothesize this could be used to reduce invasive surgery.
Experts debate second-line tivozanib for advanced renal cell carcinoma, weighing PFS gains, tolerability, and whether continuing immunotherapy adds real benefit.
Experts weigh IO-TKI vs dual immunotherapy for metastatic ccRCC, highlighting rapid symptom relief, bone/brain response, survival outcomes, and toxicity tradeoffs.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma
2
MC001 Receives FDA Fast Track Designation in Pancreatic Cancer
3
FET-PET, Molecular Testing, and Personalized Treatment Push Brain Tumor Care Forward
4
Vilamakitug Meets Phase 2 Efficacy Criterion in Refractory Metastatic Colorectal Cancer
5